Article
Infectious Diseases
Carlos Diaz-Arocutipa, Beatriz Melgar-Talavera, Angel Alvarado-Yarasca, Maria M. Saravia-Bartra, Pedro Cazorla, Ivan Belzusarri, Adrian Hernandez
Summary: The use of statins in COVID-19 patients was found to be associated with a lower risk of mortality based on adjusted effects of cohort studies. However, more randomized controlled trials are still needed to confirm these findings.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
(2021)
Article
Medicine, General & Internal
Ippazio Cosimo Antonazzo, Carla Fornari, Davide Rozza, Sara Conti, Raffaella Di Pasquale, Paolo Angelo Cortesi, Shaniko Kaleci, Pietro Ferrara, Alberto Zucchi, Giovanni Maifredi, Andrea Silenzi, Giancarlo Cesana, Lorenzo Giovanni Mantovani, Giampiero Mazzaglia
Summary: The prior use of statins among patients with established cardiovascular diseases who are hospitalized with COVID-19 was not associated with an increased risk of mechanical ventilation or intensive care unit access, but it was associated with a decreased risk of mortality at 30 days. These findings support the continued use of statins in patients with cardiovascular diseases during SARS-CoV-2 infection.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Geriatrics & Gerontology
Elena Izkhakov, Yair Vilian, Assaf Buch, Veronika Denysov, Dima Namouz, Alexandra Nathan, Yona Greenman, Tomer Ziv-Baran
Summary: This study evaluated the association between preadmission statin use and the clinical presentation and outcomes of COVID-19 patients older than 70 years of age. The study found that preadmission statin use was associated with a lower risk of adverse outcomes in hospitalized COVID-19 patients. Continuation of statin treatment may help reduce the risk of adverse outcomes in older adults in the era of new SARS-CoV-2 variants and less effective vaccines.
Article
Medicine, General & Internal
Laura Andrews, Laurel Goldin, Yan Shen, Kimberly Korwek, Kacie Kleja, Russell E. Poland, Jeffrey Guy, Kenneth E. Sands, Jonathan B. Perlin
Summary: Discontinuation of previous atorvastatin therapy is associated with worse outcomes for COVID-19 patients. Continuous use of atorvastatin reduces the odds of mortality and ventilation.
JOURNAL OF HOSPITAL MEDICINE
(2022)
Article
Medicine, General & Internal
H. G. Gaitan-Duarte, C. Alvarez-Moreno, C. J. Rincon-Rodriguez, N. Yomayusa-Gonzalez, J. A. Cortes, J. C. Villar, J. S. Bravo-Ojeda, A. Garcia-Pena, W. Adarme-Jaimes, V. A. Rodriguez-Romero, S. L. Villate-Soto, G. Buitrago, J. Chacon-Sarmiento, M. Macias-Quintero, C. P. Vaca, C. Gomez-Restrepo, N. Rodriguez-Malagon
Summary: This study aimed to evaluate the effectiveness and safety of rosuvastatin plus colchicine, emtricitabine/tenofovir, and their combined use in hospitalized patients with COVID-19. The findings suggest that the combined use of FTC/TDF+COLCH+ROSU reduces the risk of 28-day mortality in these patients compared to standard care. More randomized controlled trials are needed to further assess the potential advantages of this treatment combination.
Review
Cardiac & Cardiovascular Systems
Anastasios Kollias, Konstantinos G. Kyriakoulis, Ioannis G. Kyriakoulis, Thomas Nitsotolis, Garyphallia Poulakou, George S. Stergiou, Konstantinos Syrigos
Summary: A systematic review was conducted to analyze the relationship between statin therapy and mortality in COVID-19 patients, showing that statin therapy was associated with about a 35% decrease in the adjusted risk of mortality.
Review
Biochemistry & Molecular Biology
Stanislaw Surma, Maciej Banach, Joanna Lewek
Summary: The global COVID-19 pandemic caused by the SARS-CoV-2 coronavirus poses a significant threat to individuals with comorbidities or dyslipidemia, but appropriate treatment, including lipid-lowering therapies, has shown potential to improve outcomes and reduce mortality rates.
LIPIDS IN HEALTH AND DISEASE
(2021)
Article
Virology
Irene Visos-Varela, Maruxa Zapata-Cachafeiro, Samuel Pintos-Rodriguez, Rosendo Bugarin-Gonzalez, Francisco Javier Gonzalez-Barcala, Maria T. Herdeiro, Maria Pineiro-Lamas, Adolfo Figueiras, Angel Salgado-Barreira
Summary: This study evaluates the effect of statin use on patients with COVID-19 and finds that chronic use of atorvastatin and simvastatin is associated with a decreased risk of hospitalization, mortality, and susceptibility to the virus.
JOURNAL OF MEDICAL VIROLOGY
(2023)
Article
Pharmacology & Pharmacy
Srikanth Umakanthan, Sanjum Senthil, Stanley John, Mahesh K. Madhavan, Jessica Das, Sonal Patil, Raghunath Rameshwaram, Ananya Cintham, Venkatesh Subramaniam, Madhusudan Yogi, Abhishek Bansal, Sumesh Achutham, Chandini Shekar, Vijay Murthy, Robbin Selvaraj
Summary: Statins have beneficial effects in reducing mortality in hospitalized COVID-19 patients by exerting anti-inflammatory, anti-thrombotic, and immunomodulatory properties.
FRONTIERS IN PHARMACOLOGY
(2022)
Review
Multidisciplinary Sciences
Ronald Chow, James Im, Nicholas Chiu, Leonard Chiu, Rahul Aggarwal, Jihui Lee, Young-Geun Choi, Elizabeth Horn Prsic, Hyun Joon Shin
Summary: Among 110,078 patients, individuals who used statins before COVID-19 hospitalization had similar mortality risk compared to non-users; however, patients administered statins after COVID-19 diagnosis had a lower risk of mortality. Statins did not reduce mortality in ICU patients, but statin users in non-ICU settings had lower mortality risk compared to non-users.
Article
Immunology
Oliver F. Wirz, Katharina Roltgen, Bryan A. Stevens, Suchitra Pandey, Malaya K. Sahoo, Lorna Tolentino, Michelle Verghese, Khoa Nguyen, Molly Hunter, Theo Thomas Snow, Abhay Raj Singh, Catherine A. Blish, Jennifer R. Cochran, James L. Zehnder, Kari C. Nadeau, Benjamin A. Pinsky, Tho D. Pham, Scott D. Boyd
Summary: The study found that early transfusion of high-titer CCP is beneficial for COVID-19 patients, and high-titer CCP should be collected within 60 days post-recovery from donors who experienced fever. Transfused antibody titers were significantly lower than endogenously produced antibodies, underscoring the importance of providing CCP prior to endogenous seroconversion.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Cardiac & Cardiovascular Systems
Jose D. Torres-Pena, Niki Katsiki, Pablo Perez-Martinez
Summary: ARDS caused by COVID-19 is the main cause of death, with patients presenting serious cardiovascular disorders. Statins can impact various pathological processes through their pleiotropic properties. This review provides a critical overview of using statins to modulate the severity of COVID-19.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2021)
Article
Biochemical Research Methods
Megan M. M. Sperry, Tomiko T. T. Oskotsky, Ivana Maric, Shruti Kaushal, Takako Takeda, Viktor Horvath, Rani K. K. Powers, Melissa Rodas, Brooke Furlong, Mercy Soong, Pranav Prabhala, Girija Goyal, Kenneth E. E. Carlson, Ronald J. J. Wong, Idit Kosti, Brian L. L. Le, James Logue, Holly Hammond, Matthew Frieman, David K. K. Stevenson, Donald E. E. Ingber, Marina Sirota, Richard Novak
Summary: Drug repurposing requires distinguishing established drug class targets from novel molecule-specific mechanisms and rapidly derisking their therapeutic potential in a time-critical manner, particularly in a pandemic scenario. In response to the challenge to rapidly identify treatment options for COVID-19, several studies reported that statins, as a drug class, reduce mortality in these patients. However, it is unknown if different statins exhibit consistent function or may have varying therapeutic benefit.
PLOS COMPUTATIONAL BIOLOGY
(2023)
Article
Medicine, General & Internal
Eduardo Barge-Caballero, Pedro J. Marcos-Rodriguez, Nieves Domenech-Garcia, German Bou-Arevalo, Javier Cid-Fernandez, Raquel Iglesias-Reinoso, Paula Lopez-Vazquez, Javier Muniz, Jose M. Vazquez-Rodriguez, Maria G. Crespo-Leiro
Summary: This retrospective study using the COVID-19 registry of a Spanish university hospital found a significant association between previous statin therapy and lower mortality in hospitalized patients with COVID-19. The greatest benefit of previous statin therapy was seen in patients with previous coronary or extracardiac arterial disease.
Article
Virology
Alvaro Goncalves Mendes Neto, Kevin Bryan Lo, Ammaar Wattoo, Grace Salacup, Jerald Pelayo, Robert DeJoy, Ruchika Bhargav, Fahad Gul, Eric Peterson, Jeri Albano, Gabriel Patarroyo-Aponte, Janani Rangaswami, Zurab Azmaiparashvili
Summary: Bacterial coinfection in patients with COVID-19 is associated with increased inpatient mortality, with genitourinary source being the most common source of bacterial infection. Patients who received antibiotic therapy had a significantly higher rate of inpatient mortality.
JOURNAL OF MEDICAL VIROLOGY
(2021)